Beijing/W Genotype Mycobacterium tuberculosis and Drug Resistance

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Beijing/W Genotype Mycobacterium tuberculosis and Drug Resistance

Published Date:

May 2006

Source:

Emerg Infect Dis. 12(5):736-743.

[PDF-228.36 KB]

Details:

Alternative Title:

Emerg Infect Dis

Corporate Authors:

European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis

Description:

Beijing/W genotype Mycobacterium tuberculosis is widespread, may be increasing, and may have a predilection for drug resistance. Individual-level data on >29,000 patients from 49 studies in 35 countries were combined to assess the Beijing genotype's prevalence worldwide, trends over time and with age, and associations with drug resistance. We found 4 patterns for Beijing/W genotype tuberculosis (TB): 1) endemic, not associated with drug resistance (high level in most of East Asia, lower level in parts of the United States); 2) epidemic, associated with drug resistance (high level in Cuba, the former Soviet Union, Vietnam, and South Africa, lower level in parts of Western Europe); 3) epidemic but drug sensitive (Malawi, Argentina); and 4) very low level or absent (parts of Europe, Africa). This study confirms that Beijing/W genotype TB is an emerging pathogen in several areas and a predominant endemic strain in others; it is frequently associated with drug resistance.

Subject:

[+]

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

Supporting Files:

	05-0400-F.gif	image/gif
	05-0400-F.jpg	image/jpeg
	05-0400.nxml	text/plain
	license.txt	text/plain

No Related Documents.

You May Also Like:

CDC COVID-19 global response

Corporate Authors:

Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication.

Published Date:

08/05/2020

Description:

Cases of coronavirus disease 2019 (COVID-19) have been detected in most countries worldwide. On Friday, March 6, 2020, President Trump signed the Coronavirus Preparedness and Response Supplemental Appropriations Act 2020 (Public Law 116-123). Title I...

File Type:

[PDF - 72.03 KB]
Presence of Segmented Flavivirus Infections in North America

Personal Author:

Vandegrift, Kurt J.; Kumar, Arvind; Sharma, Himanshu; Murthy, Satyapramod; Kramer, Laura D.; Ostfeld, Richard; Hudson, Peter J.; Kapoor, Amit;

Published Date:

August 2020

Source:

Emerg Infect Dis. 26(8):1810-1817

Description:

Identifying viruses in synanthropic animals is necessary for understanding the origin of many viruses that can infect humans and developing strategies to prevent new zoonotic infections. The white-footed mouse, Peromyscus leucopus, is one of the most...

File Type:

[PDF - 1.51 MB]
Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recomm Rep 2020;69(No. RR-7).

Personal Author:

Cole B, Nilsen DM, Will L, et al.

Published Date:

07/31/2020

Source:

MMWR Recomm Rep 2020;69(No. RR-7)

Series:

MMWR Recommendations and Reports

Description:

SUPPLEMENTARY APPENDIX A: Responsibilities of the Tuberculosis Controller or Tuberculosis Program Manager; SUPPLEMENTARY APPENDIX B: Core Public Health Functions and Essential Services; SUPPLEMENTARY APPENDIX C: CDC-Funded Resources; SUPPLEMENTARY AP...

File Type:

[PDF - 698.42 KB]
Interim operational considerations for implementing the shielding approach to prevent COVID-19 infections in humanitarian settings

Corporate Authors:

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.

Published Date:

07/29/2020

Description:

This document presents considerations from the perspective of the U.S. Centers for Disease Control & Prevention (CDC) for implementing the shielding approach in humanitarian settings as outlined in guidance documents focused on camps, displaced popul...

File Type:

[PDF - 250.15 KB]
Interim operational considerations for implementing the shielding approach to prevent COVID-19 infections in humanitarian settings

Corporate Authors:

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.

Published Date:

July 26, 2020

Description:

Updated July 26, 2020This document presents considerations from the perspective of the U.S. Centers for Disease Control & Prevention (CDC) for implementing the shielding approach in humanitarian settings as outlined in guidance documents focused on c...

File Type:

[PDF - 250.15 KB]